RxDoctor Payments Data

Aritra Sen, MD

Pulmonary Disease · Richardson, TXNPI 1760801955

Payments from drug & device makers

$6,376in general payments, 2019–2025

Across 100 payments — averaging $63.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$440
  • AstraZeneca$341
  • Ceribell, Inc.$163
  • Sanofi$137
  • Baxter Healthcare$131
  • plus $765 from 17 others

What the payments were for

  • Travel & lodging$1,39822%
  • Food & beverage$1,97831%
  • Education$3,00047%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,376 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$235,081
Medicare patients
474
Services billed
1,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$107,476
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$37,717
Spiriva RespimatTiotropium Bromide45$27,876
Breo ElliptaFluticasone/Vilanterol28$14,387
Combivent RespimatIpratropium/Albuterol Sulfate19$9,552
Spiriva HandihalerTiotropium Bromide13$9,236
SymbicortBudesonide/Formoterol Fumarate24$7,066
Arnuity ElliptaFluticasone Furoate23$6,671
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$2,935
Roflumilast31$2,306
Albuterol Sulfate HfaAlbuterol Sulfate71$2,043
Ventolin HfaAlbuterol Sulfate27$1,495
Azithromycin103$800
Fluticasone Propionate47$776
Omeprazole62$643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$440$128,535195 claims
AstraZenecaBreztri Aerosphere, Symbicort$341$44,78369 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$71$37,42864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →